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1. Introduction 
Allergic conjunctivitis (AC) is an inflammation of the conjunctiva secondary to an immune 
response to external antigens, usually called allergens. This inflammation could be IgE-
mediated and non-IgE mediated and atopy could play a significant role in clinical evolution. 
(Johansson et al., 2004) AC is not a single disease; in fact it is a syndrome affecting the entire 
ocular surface, including conjunctiva, lids, cornea, and tear film. The signs and symptoms of 
allergic conjunctivitis have a meaningful effect on comfort and patient health, and are 
influenced by genetics, environment, ocular microbiota, and immune regulation 
mechanisms, all of which work together in a complex immunological response. 
Dysregulation in such immune homeostasis could turn into a variety of allergic ocular 
diseases (AOD). This chapter describes the current understanding of cellular and molecular 
pathways involved in different AOD, the clinical characteristics of ocular allergies, the new 
therapies related to control of immune activation, and the importance of basic research to 
generate new types of immunotherapy to treat allergic conjunctivitis 
2. Immunological mechanisms of allergic conjunctivitis 
Two stages have been defined in AC immune pathophysiology. The first stage is named 
sensitization phase reaction, and is initiated by preferential activation and polarization of 
the immune response to environmental antigens, that culminates with a generation of a 
predominant Th2 immune response and production of IgE antibodies; the second stage, 
named effector phase reaction, is initiated with a second encounter with antigen (Ag) 
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leading to activation of effector mechanisms, such as degranulation of granulocytes and 
release of histamine (Abelson et al., 2003). 
2.1 Sensitization phase reaction 
It has been reported in patients with asthma (Takhar et al., 2007) and allergic rhinitis 
(Takhar et al., 2005), that both, bronchial and nasal mucosa, have the ability to capture Ag 
trough Langerhans cells (LC). LC could process and present Ag in the context of MHC-II 
molecules and stimulate specific CD4+T cells to induce secretion of interleukin (IL)-4, IL-13 
and expression of CD154; this process activates genetic recombination in B cells and class 
switching to IgE. Similar mechanism could be involved in ocular mucosa, since it has been 
reported that IgE could be detectable in human tears (Allansmith et al., 1976) and B cells 
located in the conjunctival lymphoid follicles are CD23+ CD21+ CD40+, suggesting that 
they might be precursors of IgE-producing B cells and contribute to local IgE synthesis (Abu 
El-Asrar et al., 2001). 
2.2 Effector phase reaction 
Allergen-induced cell degranulation is the key event in allergic inflammation and leads to 
early-phase symptoms. Early phase reaction (EPR) has been studied extensively in both 
humans and animals; EPR is initiated with a second encounter with the antigen by IgE 
previously attached to IgE receptors (Fc┝RI, Fc┝RII or CD23). Cross-linking of IgE receptors 
induces: a) release of preformed mediators such as histamine, proteases and chemotactic 
factors; b) activation of transcription factors and cytokine gene expression, and c) production 
of prostaglandins and leukotrienes by phospholipase A2 pathway. Activation of mast cells by 
IgE in conjunctiva is relevant since it is well known that there are up to 6000 cell/mm3 in 
conjunctiva (Bielory, 2000) and mast cell density is increased in acute and chronic 
conjunctivitis patients (Anderson et al., 1997; Morgan et al., 1991). Activated mast cells can 
release several cytokines such as IL-4, IL-6, IL-13, and Tumor Necrosis Factor (TNF) 
contributing to increase local inflammatory Th2 response (Anderson et al., 2001; Cook et al., 
1998), and also are able to increase Fc┝RI density in chronic keratoconjunctivits (Matsuda et al., 
2009). On the other hand, cellular infiltration is the main feature of the late phase reaction 
(LPR). LPR begins 4-24 hr after EPR, and involves the infiltration of inflammatory cells, 
basophils, neutrophils, T Lympocytes, and mainly eosinophils (Choi & Bielory, 2008). Animal 
models of AC have shown that inflammatory migration is directed by T cells; recently, a 
relevant role for ┛├ T cells have been suggested since TCR┛├ (-/-) mice have shown a 
decreased clinical manifestations and eosinophilic infiltration compared with wild type mice 
(Reyes et al., 2011); however, involvement of ┛├ T cells in human AC is still unknown. Once 
initiated, LPR can proceed in the presence of little or no detectable allergen-specific IgE 
antibody. LPR can also be induced by adoptively transference of T cells from allergen-
sensitized donors to naïve recipients prior to challenging the ocular surface with the specific 
antigen (Fukushima et al., 2005). LPR could lead to corneal complications secondary to 
eosinophil infiltration. Eosinophils are attracted to ocular surface due to ligation of eotaxin- 
CC-chemokine receptor (CCR) 3 or RANTES-CCR1 (Heath et al., 1997). Notably, CCR3 
chemotaxis induced by culture supernatant from corneal keratocytes and tear samples from 
severely allergic patients, could be inhibited by specific monoclonal antibodies against CCR3 
(Fukagawa et al., 2002). Basophil infiltration could also be associated with AC because these 
cells express CCR3 and contribute with direct damage through Fc┝RI degranulation. 
Interestingly in a mice model of AC basophil activation could also be induced by IL-33, 
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resulting in IL-4 and IL-13 expression, and potentiation of IgE-mediated degranulation 
(Matsuba-Kitamura et al., 2010). However, during the active inflammatory phase of the 
disease, multiple Th1-type and Th2-type cytokines are over expressed and produced 
(Leonardi, et al., 2006; Aguilar-Velazquez et al., 2009), including the typical Th1-type cytokine, 
interferon (IFN)-┛ and TNF, which might probably contribute to increase ocular 
inflammation similarly to animal models (Stern et al., 2005; Fukushima et al., 2006). The Th1-
cells could also play a pivotal role in the delayed hypersensitivity ocular damage, through cell-
mediated mechanisms, acting as a counter-balance factor to the Th2-cells, during antigen 
presentation and in the activation/inhibition of other cell types. Delayed hypersensitivity 
damage has also been suggested in asthma and nasal allergy (Pelikan, 2010; Pelikan, 2011) 
2.3 Different cell populations and its impact in ocular allergy 
Despite the role of dendritic cells (DC) have been extensively studied in animal models, 
other antigen presenting cells (APC) are still in research. Recently it has been suggested that 
macrophages could be needed in the development of experimental AC, since it appears they 
are able to take up antigen-labeled and act as APC (Ishida et al., 2010); nevertheless, further 
research in human patients is needed to know the real role of macrophages in AC. In 
addition, fibroblasts, conjunctival and corneal epithelial cells may contribute to human 
allergic inflammation by expressing and producing cytokines, chemokines, adhesion 
molecules and factors that maintain local inflammation and lead to tissue remodeling 
(Bonini et al., 2000; Leonardi et al., 2006).  
2.4 T regulatory cells (Tregs) 
An increasing number of reports have demonstrated that Tregs suppress allergic specific 
response (Akdis et al., 2004). In support of the important role of Tregs in controlling allergic 
diseases, it was demonstrated that CD4+CD25+ T cells protect against experimentally 
induced asthma, diminishing airway inflammation and hyper-reactivity after in vivo transfer 
of CD4+CD25+ regulatory T cells in IL-10 dependent manner (Lewkowich et al., 2005). In 
animal models of AC it has been suggested that induction of CD4+CD25+Foxp3+ T cells 
suppress the development of experimental allergic conjunctivitis through stimulation of 
alpha-galactosylceramide (Fukushima et al., 2008). Unfortunately research about 
involvement of Tregs in human AC is not enough yet.  
2.5 Other T cell populations 
Although in other allergies is well known the involvement of Th9, Th17, Th22, and NKT cells 
in effector responses, a long way in research is still pending in AC in both, human and animal 
models. Additionally, other molecules such as Toll like receptors (TLR) and Nucleotide 
Olimerization Domain (NOD) receptors that are expressed in epithelial cells, DC and T cell 
subsets (Bauer et al., 2007) could be modulating the immune response in unexpected ways 
depending of ocular microbiota, thus AC must be a field of extensive research. 
3. Clinical aspect of allergic conjunctivitis 
3.1 Classification of allergic ocular diseases 
Allergic conjunctivitis includes a spectrum of a number of traditional overlapping 
conditions that range from intermittent to persistent symptoms and signs, variable in 
severity and presentation. These forms include seasonal (SAC) and perennial allergic 
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conjunctivitis (PAC), vernal keratoconjunctivitis (VKC) and atopic keratoconjunctivitis 
(AKC). Giant papillary conjunctivitis (GPC), and contact or drug-induced 
dermatoconjunctivitis (CDC) are considered as subtypes of allergic conjunctivitis, due to 
their mechanism of allergy. (Leonardi et al., 2007). 
Patients with mild forms of AC report symptoms with active signs not always seen at the 
time visit. Some of these symptoms include runny nose, sneezing, and or/wheezing. 
Classic reports describe allergic rhinitis and symptoms of watery (88%), itchy (88%), red 
(78%), sore (75%), swollen (72%) and stinging eyes (65%) (Dykewicz & Fineman, 1998). 
The main symptom of ocular allergy is itching, without itching; a condition should not be 
considered ocular allergy. Clinical manifestations of the effects of eye rubbing include 
injection of conjunctival vascular bed due to vascular dilation evoked by vasoactive 
amines released during mast cell degranulation, accompanied by an influx of water from 
the intravascular space, to the extravascular space, resulting in tissue edema and eyelid 
swelling, progressing from a milky or pale conjunctiva aspect to conjunctival swelling or 
chemosis. Swelling appears 15-30 minutes after antigen exposure and slowly diminished; 
a small quantity of white mucus secretion may form during the acute phase which can 
later becomes thick strands in the chronic form. In chronic forms a remodeling process is 
induced in conjunctiva tissue as fibrosis with vascularization that can be easily identified 
with slit lamp (Ono & Abelson, 2005) 
There are numerous classifications for AOD according to the underlying pathophysiology 
and clinical findings. Common signs and symptoms exist in the different types of allergic 
disorders with frequent overlapping between SAC, PAC (acute forms of allergic 
conjunctivitis), VKC and AKC (chronic forms of conjunctivitis); therefore, classifications are 
recommended to standardize disease based on signs and symptoms, (mild, moderate or 
severe), (Abelson et al., 1990; Uchio et al., 2008; Pelikan, 2009) length of the disease (acute vs 
chronic disease), mechanism of immunopathogenesis (EPR and LPR stages), and duration of 
episodes activity (quiescent, intermittent and persistent), only suggested to VKC and AKC 
(Bonini et al., 2007; Calonge & Herreras, 2007), since they impact the quality of life. Such 
matter is important and should be consider in AOD diagnosis, similar to other allergic 
diseases (Del Culvillo et al., 2010). Although it has been suggested that SAC and GPC are 
milder and there is not involvement of the cornea, PAC and CDC might have a moderate 
risk of sight threatening, while VKC and AKC are the most serious forms of AC (Tanaka et 
al., 2004; Foster & Calonge, 1990). Therefore a grade of severity, in terms of signs and 
symptoms, is crucial to establishment of ocular clinical status, and possible vision 
compromise in AC patients.  
3.2 Evaluation of grade of severity for allergic ocular diseases 
The most common way to identify severity based mainly on conjunctiva, palpebral or 
cornea inflammation are mild, moderate or severe; however to better assess clinical 
characteristics in AOD groups, and to evaluate possible evolution of AC, the authors 
propose here, besides to take all recommendations mentioned above,  a grading system 
based on a scale of 0 to 4, when 0=absent, 1=mild, 2=moderate, 3=moderately severe, and 
4=severe, for both signs and symptoms. Taking in consideration, frequency in symptoms 
(itching, tearing, light sensitivity, gritty sensation, and burning sensation), (Table 1) and 
repercussion of signs implicated on alterations accompanying the inflammation at the 
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ocular surface, such as eyelid position and skin aspect, eyelid margin state of 
mucocutaneous junction (MCJ) with involvement of meibomian gland disease (MGD), 
discharge aspect, implication of limbal stem cell deficiency and even keratoconus 
involvement. (Figure 1 and Table 2) The total score of signs and symptoms following 
grade of severity scale would give a total amount of 48 points, twenty of them 
corresponding to symptoms, and twenty eight of them corresponding to signs. According 
to this statement, we propose an objective grading system to recognize progress of allergic 
ocular disease, which could be defined as follows: 0 points= Absent, 1-12 points (mild), 
13-24 points (moderate), 25-36 points (moderately severe) and 36-48 points (severe). The 
score of the more severe side in bilateral cases could be used as a clinical score. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Evaluation of Grade of Symptoms Severity for Allergic Ocular Diseases 
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Table 2. Evaluation of Grade of Signs Severity for Allergic Ocular Diseases 
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Fig. 1. Evaluation of Grade of Signs Severity for Allergic Ocular Diseases.  
3.3 Acute forms of allergic conjunctivitis 
3.3.1 Seasonal allergic conjunctivitis and perennial allergic conjunctivitis 
Mild forms of SAC and PAC are entities which often go undiagnosed, as well as the 
ocular component of allergic rhinoconjunctivitis that can go also untreated. Both are acute 
forms of presentation and are mainly non-sight threatening conditions. Symptoms 
associated with SAC condition, such as ocular itching and redness, are often accompanied 
with tearing and nasal congestion (Wormald etal., 2004). Both, SAC and PAC patients, can 
also manifest symptoms of irritation, burning and foreign body sensation that might be 
related to increased tear film lipid layer thickness or even alterations of the lipid 
secretions, causing tear instability with diminished break up time (Suzuki et al., 2006). 
Eosinophilic activation and concomitant release of inflammatory mediators, which are 
thought to be detrimental to conjunctival epithelia and globet cells, are considered the 
cause of tear film instability (Lobefalo et al., 1999). It has been suggested that PAC 
patients are sensitized to house dust mite, animal dander and moulds, which are present 
all year round (Dart et al., 1986). However, we have observed that in our patients 
(Mexican mestizo population) both, SAC and PAC patients, are sensitized to house dust 
mite. The clinical characteristics of SAC and PAC patients can be seen on figure 1 and 
table 2 and correspond mainly to grade 1 and 2.  
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3.4 Chronic forms of conjunctivitis 
3.4.1 Vernal keratoconjunctivitis 
VKC is a chronic ocular surface inflammatory condition most commonly observed in young 
males before puberty living in dry, warm climates. VKC is bilateral and characterized by 
seasonal or perennial symptoms that exacerbate with recurrences in 60% during spring, 
early autumn and winter. Prolonged inflammation, more than 3 years, leads to a greater 
chance of developing perennial symptoms. During exacerbations, intense itching is the 
predominant feature, followed by photophobia, tearing, and sticky mucus discharge (Bonini 
et al., 2000). VKC has a wide range of conditions and all of them are not necessarily present 
at the time of visit, and could be a manifestation of disease evolution. The disease may 
primarily involve the tarsal or limbal conjunctiva leading to different forms of VKC: tarsal, 
limbal or mixed forms. In tarsal VKC, there is important hyperemic conjunctiva, chemosis 
and hypertrofic papillae 0.5-0.75 mm size with a cobblestone appearance representing the 
hallmark of disease. Typical Maxwell-Lyons sign is recognized for thick strands of mucus 
over papillaes. In limbal VKC gelatinous yellow-gray infiltrates are observed on the limbus, 
the circumference of which might appear thickened and opaque, with a peripheral and 
superficial neovascularization. Horner-Trantas dots are white, calcareous-like cellular 
infiltrates with eosinophil reaction occurring on the edge of limbal conjunctiva and also on 
top of nodules. Cornea involvement consider superficial punctate keratopathy, corneal 
erosions, indolent superficial ulcer (shield ulcers) which develops with opaque edges and 
plaque formation through deposition of mucus and cells, mainly located at the superior 
quadrants. VKC is also associated with keratoconus, which in fact should be a mandatory 
condition to search, because there are a 6% of patients that might end up with permanent 
reduction in visual acuity as a result of the cornea compromise. The higher incidence of 
compromise due to persistent disease at the ocular surface occurs with chronic limbal 
inflammation leading to gradual loss of stem cell function as a result of insufficient 
stromal support, ending up with limbal stem cell deficiency, and conjunctival fibrosis 
(Sangwan et al., 2005). Fibrosis could be associated with high immunostaining of positive 
mast cells to TGF, bFGF, and PDGF (Leonardi et al., 2000). Characteristic signs of VKC 
patients correspond to grade 2 and mainly 3. (Figure 1 and Table 2)  
3.4.2 Atopic keratoconjunctivitis 
AKC is a chronic ocular surface inflammatory response in men aged 30 to 50 years 
(Leonardi et al., 2007), however we have identified onset as earlier as in the first decade of 
life (Mexican mestizo population). It might be depending on severity a sight-threatening 
condition. The primary symptom of AKC is intense bilateral itching of the lid skin, 
periorbital area, and conjunctiva. Ocular symptoms also include photophobia, burning and 
foreign body sensation. Atopic blepharitis is evident, with tylosis and swollen eyelids that 
have a rugosity aspect with indurated appearance and associated with meibomian gland 
disease and concomitant dry eye (Onguchi et al., 2006). Infraorbital skin of the eyelid is 
frequently affected by single or double infraorbital creases known as Dennie-Morgan lines, 
which are caused by edema or thickening of the skin. Absence of the lateral eyebrow 
(Hertoghe sign) is present in many older patients and may be due to extensive chronic eye 
rubbing (Rich & Hanifin, 1985) and in the most severe cases conjunctival scarring with 
subepithelial fibrosis, fornix foreshortening, symblepharon, corneal ulceration and 
neovascularization may occur. Manifestations involving other tissues in the context of atopic 
dermatitis (episcleritis, scleritis, uveitis, keratoconus, cataract, and retinal detachment) must 
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be considered. AKC is related with an increased risk of secondary infections, including 
bacterial, herpetic keratitis and Chlamydia trachomatis infections (Forte et al., 2009). There is 
discrepancy of evolution among AKC, the main reason for this is the overlapping of clinical 
pictures due to possible shift from VKC to AKC in those VKC patients that allergy did not 
disappear during puberty or adulthood as typical VKC does. These patients usually have at 
the beginning signs of AKC when they transform into adults, but most probably conserve 
giant papillary reaction at the upper tarsal conjunctivas. Characteristic signs of AKC 
patients correspond to grade 3 and mainly 4. (Figure 1 and Table 2)  
3.5 Subtypes of allergic conjunctivitis 
3.5.1 Giant papillary conjunctivitis (GPC) 
It is not a true ocular allergic reaction, as is the case with SAC, PAC, VKC, and AKC. It is a 
mild ocular allergy caused by repeated mechanical irritation (contact lens wearers, ocular 
prosthesis, exposed sutures) and is aggravated by concomitant allergy, with an increase of 
symptoms during spring pollen season. (Leonardi et al., 2007) It is present during the 2nd to 
5th decade of life. Symptoms of blurred vision, foreign body sensation, itching and tearing 
are present. Signs of mucus production with abnormal thickening of conjunctiva and visible 
white appearance on papillae with white or clear exudates, thick and stringy on awakening 
become a particular picture, in a chronic manner. Upper tarsal papillary hypertrophy has 
been described in 5% to 10% of soft and 3% to 4% of hard contact lens wearers. GPC is 
associated with the infiltration of basophils, eosinophils, plasma cells, and lymphocytes, 
which suggest a mixed mast cell- and lymphocyte-mediated process. (Chang & Chang, 2001) 
3.5.2 Contact blepharitis or dermatoconjunctivitis 
This type of reaction implies the eyelid skin and surrounding orbital limits. It is related to 
contact T- cell-mediated delayed hypersensitivity reaction to haptens-carrier complex such 
as cosmetics, metals, and chemicals as well as topical preparations with drugs or 
preservatives involved. Symptoms of eyelid itching, eczema, conjunctival redness and 
punctate keratitis might be seen. There is a participation of Langerhans cells of the eyelid 
skin or conjunctiva and presented to T-helper lymphocytes in the regional lymph nodes , 
which in turn sensitized cells react with cytokines resulting in recruitment and activation of 
inflammatory cells and resident cells. (Leonardi et al., 2007) 
3.6 Other clinical allergic conditions and its impact in allergic ocular diseases 
3.6.1 Ear nose and throat (ENT) co-morbilities 
It is well known that allergic rhinitis could be present during allergic conjunctivitis. Specific 
nasal symptoms includes nasal congestion, nasal discharge or rhinorrhea, sneezing, hyposmia, 
breathing alterations, nasal voice, nose bleeding, and in some cases turbinate hypertrophy, and 
polypoid degenerations (De Groot et al., 2007). Mucosal edema of the upper airways induces 
changes in the nasal physiological equilibrium (Al-Rawi et al., 1998). Causes related to 
exacerbation of mucosal reactivity comprise intrinsic and extrinsic factors. Intrinsic factors 
include allergies, metabolic disorders, and anatomical alterations; while extrinsic factors 
encompass relative humidity, temperature, pollution, barometric pressure, among others. All 
of these alterations induce an inflammatory process that could be self limited or persistent, 
leading to more inflammatory responses (Nacleiro et al., 2010). Mucosal inflammation also 
stimulates mucin hypersecretion (Yuta et al., 1997), and if inflammatory process continues, 
drainage system fails and retrograde complications develops, such as paranasal sinus 
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dysfunction, nasolacrimal duct occlusion and middle ear alterations. Paranasal sinus 
dysfunction generates stasis of nasal secretions, edema and sinus infection (Ryan & Brooks, 
2010). Severe ocular complications due to sinus infection include periorbital cellulitis, and 
cavernosus sinus thrombosis (Moubayed et al., 2011). Nasolacrimal duct occlusion is related 
with persistent epiphora and ocular infections. (Annamalai et al., 2003) Middle ear alterations 
include inflammation of Eustachian tube, generating low pressure in the middle ear. Changes 
in middle ear pressure develops in “glue ear” (middle ear fluid with increased viscosity), 
decreased audition, and in some cases mechanical vertigo (Pelikan, 2009). 
Complications mentioned above can be prevented if the treatment of the rhinitis is just on 
time. Diagnostic management requires analysis of symptoms, physical examination, 
searching for eosinophilia in nasal secretions, and total IgE determination. Computerized 
tomography scan is a mandatory to study paranasal sinus complications (Lee et al., 2008). 
Treatment depends of each patient and if complications are present or not. The core of 
treatment must be directed to restructure the physiological nasal function. In this context, 
we have observed that treatment of AOD gets very favorable results in nasal symptoms; 
similarly, control of allergic rhinitis induces a better ocular outcome. 
3.6.2 Skin co-morbidities 
Patients with allergic ocular disease may have, among other systemic allergic co-morbidities, 
immune-mediated skin disorders. While AKC has been commonly associated with atopic 
dermatitis (AD), other types of AC may also be associated with conditions such as contact 
dermatitis (CD), urticaria and angioedema (Calonge, 2000). Early onset of AD is commonly 
regarded as the first manifestation of the so-called “atopic march”, where asthma and allergic 
rhinoconjunctivitis arise eventually in patients previously suffering from AD (Spergel & Paller, 
2003) (Figure 2). Conjunctival and corneal involvements among patients with AD are common 
signs in AKC. It has been speculated that AD with ocular involvement could be the most 
severe end of the spectrum of this chronic relapsing cutaneous disease characterized by 
erythematous pruritic vesicles that may evolve into chronic lichenified lesions (Spergel & 
Paller, 2003). AD and AKC may not run parallel courses; in some cases the only manifestations 
of AD may be limited to the eyelids with eczema and keratinization, as well as chronic 
blepharitis (Tuft et al., 1991). Interestingly, it has been demonstrated that AD patients have a 
marked deficiency of IgA in sweat and tear samples, which could account, at least in part, for 
the increased susceptibility to Staphylococcus aureus and Herpes simplex virus infections in the 
skin and ocular surface (Guglielmettia et al., 2010). Patients with AD may also have a higher 
tendency to present CD, and so do patients with allergic ocular disease (Calonge, 2000). CD 
may respond to allergic or irritant mechanisms that cause the development of scaly 
eczematous lesions. In patients with dermatoconjunctivitis, these lesions may be limited to the 
periorbital skin and be secondary to the application of cosmetics or topical ophthalmologic 
medications; lesions usually self resolve after discontinuing the offending agent. In patients 
with AC, acute urticarial lesions characterized by migrating edematous, pruritic plaques with 
serpiginous borders may develop. Likewise, patients may also develop angioedema, 
presenting with well-demarcated, non-pruritic areas of deeper cutaneous edema in the eyelids 
or perioral zone. When mediated by IgE, both urticaria and angioedema, are frequently 
encountered in atopic individuals, and therefore in patients with AOD. 
CD, urticaria and angioedema tend to be self limited in patients with AC, patients with AKC 
usually have relapsing chronic courses of AD. Hence, these patients could possibly benefit 
from therapies capable of simultaneously targeting the ocular and cutaneous aspects of their 
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disease. One such approach could be the use of topical tacrolimus applied to the eyelids and 
subsequently spread over the conjunctiva in patients with skin involvement limited to the 
periorbital zone (Zribi et al., 2009). Other promising therapeutic possibilities could include 
the use of systemic immunosuppressive agents, such as cyclosporine, azathioprine and 
mycophenolate mofetil (Guglielmettia et al., 2010). Finally, immunobiological therapies such 
as infliximab (anti TNF-), alefacept (T-cell inhibition) or rituximab (anti CD20) have proven 
to be effective in patients with AD, and could be of benefit in patients with AKC 
(Guglielmettia et al., 2010). 
Actinic Conjunctivitis. It has been described in the dermatologic literature as part of a 
condition termed Actinic Prurigo. Is thought to be a photosensitive reaction to ultraviolet 
light in susceptible individuals; rather than primarily an allergic response. Begins in 
childhood and involves mainly the skin, oral mucosa and the conjunctiva. It has been 
described in Indian or Mestizo heritage located in Mexico or the Andean Regions of South 
America and in the American Indian population in the southwestern of United States. 
Typical characteristics consist of localized redness on the temporal side of bulbar 
conjunctiva advanced lesions becoming thicker and more congested with pigmentary 
changes, until invasion of limbus causing a linear leukoma. (Figure 2) Actinic conjunctivitis  
 
      
(a)     (b) 
 
(c) 
Fig. 2. Skin co-morbilities in patients with AC. Clinical pictures of Atopic Dermatitis in neck 
(a); Actinic Conjunctivitis (b); and Actinic Prurigo in forearm (c) 
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has infiltration of epithelium by inflammatory cells and stromal changes with plasmacytic 
infiltrate, vascular congestion and varying numbers of eosinophils as the source of the 
lesion. Children with actinic conjunctivitis frequently complain of a burning itchy sensation 
and relief is gained with the use of steroids. Actinic conjunctivits, in its earliest stages, is 
frequently misdiagnosed as vernal conjunctivitis but without papillary reaction (Engel et al., 
2009). Despite that actinic conjunctivitis could be considered as a differential diagnosis, 
authors have observed that in some cases could coexist with AOD. 
4. In vivo diagnostic and research procedures 
Provocation tests are used to know the immediate or delay immune response against 
several allergens; these tests have high specificity and positive predictive value, and are 
the most important in vivo diagnostic and research procedures, some of these allergy 
examinations include: 
Conjunctival provocation test (CPT) 
CPT is used to determine the extent of conjunctival reaction to allergens. A drop of 
antigen to evaluate is applied to one eye, whereas a drop of balanced salt solution (BSS) is 
applied to the other eye as a control. Eyes must be examined using slit-lamp at different 
times. To control and degrade allergic eye reaction, a drop of topical antihistamine is 
applied at the end of CPT. CPT could be used as a model of ocular allergy to study ocular 
response to allergenic stimuli, and to evaluate antiallergic therapy. Considerable useful 
information has been gained on the ocular allergic response and drug efficacy using the 
CPT and naturally occurring seasonal allergic conjunctivitis. (Mortemousque, 2007; 
Kasetsuwan et al., 2010).  
Nasal provocation test (NPT) 
NPT is used to determine nasal and/or conjunctival reaction to allergens. NPT has been 
used primarily as a research tool for the investigation of allergic and nonallergic rhinitis 
with a wide variety of techniques depending on the specific scientific purposes. NPT could 
be a valuable supplementary diagnostic parameter for late nasal response (Pelikan & 
Pelikan-Filipek, 1989; Litvyakova & Baraniuk, 2001)  
Epicutaneous skin test (EST) 
EST or Skin Prick Test (SPT) provides a pivotal role in the allergy evaluation, is used to aid 
establishment of allergic symptoms and specific allergic triggers, and help to evaluate the 
degree of sensitivity to a specific agent. Many devices are available to perform testing. These 
devices attempt to allow the performer to achieve reproducible and accurate skin test results 
when standardized extracts are employed. It has been suggested high correlations between 
positive results to properly performed epicutaneous skin tests and the results of eye, nose, 
or lung challenges with the homologous allergen. The results of EST are also higly 
correlated with the results of in vitro tests and clinical histories. These correlations between 
the tests and challenges are highest when potent, well-characterized allergen extracts are 
used. For most common allergens, the results of Intracutaneous skin test (IST) add little if 
anything to correlations between skin test results and the results of challenges or to 
predicting clinical histories. The extra sensitivity of IST valuable when high potency of 
extracts are not available or when the test risk of a falsely negative test is high, as with drug 
or insect venom allergies. All physicians caring for patients with histories suggestive of 
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allergic disorders must be keenly aware of the strengths and limitations of all available 
methods. (Ownby, 2001) 
Atopy patch test (APT) 
This test is able to identify triggering factors and consist of the epicutaneous application of 
allergens for 48 hours, with an evaluation of eczematous lesions induced after 48 and 72 
hours, according to the reading criteria of the European Task Force on Atopic Dermatitis 
(ETFAD). APT show a higher specificity in atopic dermatitis than skin prick and specific IgE 
tests, since the pathophysiological mechanism of the reaction induced is very similar to that 
which occurs in AD lesions. (Nosbaum et al., 2010) Thus, optimization of APTs and progress 
in the knowledge of the pathophysiology of eczemas associated to ocular diseases could 
help to develop new immunobiological diagnostic methods and specific immunotherapy 
that could be used in AOD with skin involvement.  
5. Conventional therapeutic intervention and new immunological treatments 
Despite that AC is frequent, often is misdiagnosed and not adequately treated. Patients with 
these conditions may present to a variety of professionals-pharmacists, general practitioners, 
allergists/immunologists, otolaryngologist, and dermatologists; unfortunately, there is a 
lack of consensus in the multidisciplinary assessment for better treatment selection.  
Treatments for allergic conjunctivitis have been continuously evolving since the early 
nineties, and several levels of therapeutic intervention have been described. Primary 
intervention is related to avoid offending antigens without pharmacological measures; 
secondary intervention is directed to control local effector functions of mast 
cells/eosinophils/basophils with H1- and H2-receptor antagonists, Disodium cromoglycate, 
Nedocromil sodium, anti-inflammatory drugs (non-steroids or steroids) (Bielory et al., 2005) 
and in severe cases, tertiary intervention with immune suppressor therapy, such as 
ciclosporin or tacrolimus has been used (Daniell et al., 2006; Vichyanond et al., 2004). 
5.1 Other therapies 
Autologous Serum (AS) has been used to treat dry eye syndrome for many years. It contains 
several growth factors, vitamins, fibronectin, albumin, lisozime and other components that 
have been considered important for corneal and conjunctival integrity (Kojima et al., 2008). 
To date few studies about AS use in AOD have been reported, improvement of signs and 
symptoms is not a constant in all patients (Goto et al., 2001; Gaytán-Melicoff et al., 2005). It 
would be interesting to replicate these studies isolating total or specific IgE from serum 
before application of autologus serum eye drops in ocular surface, because is a possibility 
that absence of improvement could be related with activation of local and migrating cells by 
Fc┝R, due to AS could contain high IgE concentrations in atopic patients.  
5.2 Immune-based therapeutic approaches  
All therapeutic interventions mentioned above are focused on topical agents in an effort 
to control “the effector side of the coin”, than “the sensitization side of the coin”. Research 
in immune-based therapeutic approaches is needed to perform deeply immunological 
changes that induce a better clinical outcome in AC patients; some of these therapeutic 
approaches are specific desensitization/immunotherapy and dialyzable leukocyte 
extracts. It is very important to clarify that both of these innovative therapies are still in 
www.intechopen.com
 Conjunctivitis – A Complex and Multifaceted Disorder 46
evaluation, and until now there are not enough scientific information to ensure its efficacy 
in the treatment of AOD.  
5.3 Specific immunotherapy 
First described by Noon and Freeman in 1911, immunotherapy is thought to be the most 
specific treatment for allergic diseases, particularly asthma and allergic rhinitis. It is 
defined as the administration of low and calculated doses of the biological extract allergen 
or allergens implicated specifically in the disease of each patient (that is determined by 
the SPT), increasing gradually until get the highest dose clinically adequate. These 
vaccines comprise a complex mixture of proteins and glycoproteins that require dedicated 
standardization procedures to ensure batch-to-batch consistency. The whole 
desensitization process takes about 3 to 5 years, but the improvement should be reported 
during the first 3 to 6 months of treatment. There have been reported many ways for its 
administration, but nowadays only two have provided efficacy and safety: subcutaneous 
and sublingual (Shakir et al., 2010).  
Possible mechanisms of action of subcutaneous immunotherapy, includes the down 
regulation of cytokines, inhibition of activation and recruitment of effector cells, and 
modulation of Th1 and Th2 balance, with IFN- secretion. This particular aspect seems to be 
of major relevance and explains by itself many of the changes related to improvement of the 
allergic symptoms in asthma and rhinitis, and the long lasting efficacy after discontinuation 
(Frew, 2010). Subcutaneous immunotherapy has been reported effective in patients with 
SAC in wich IgE-mediated hypersensitivity has been demonstrated with a convincingly 
diagnostic procedure. (Kari & Saari, 2010) 
In the case of sublingual immunotherapy (SLIT), it has been reported that allergen is 
captured within the oral mucosa by Langerhans dendritic cells expressing high-affinity IgE 
receptors, producing IL-10 and TGF-, and upregulating indoleamine dioxygenase (IDO), 
suggesting that such cells are prone to induce tolerance by T regs (Scadding et al., 2010). In 
humans, SLIT is capable to reduce the proliferative response of T lymphocytes and the 
inflammatory phenomena (cellular infiltration and adhesion molecule expression on 
epithelia) in nose and conjunctiva of atopic subjects, decrease methacholine responsiveness 
and, even it does not affect IgE levels, there are an increase of IgG1 and IgG4 (Moingeon et 
al., 2006). SLIT has been used in treatment of rhinoconjunctivitis, it success has been 
reported moderately effective in reducing total and individual ocular symptom scores 
(Calderon et al., 2011). Unfortunately, not convincing specific data have been presented to 
demonstrate if SLIT is significant effective during treatment of AOD and more clinical 
studies are needed to recognize the relevance of this therapy. 
5.4 Dialyzable leukocyte extracts (DLE) 
DLE or Transfer Factors, were described by Lawrence in 1955, who proved that the extract 
obtained from a dialyzed of viable leukocytes from a health donor presenting a positive 
percutaneous tuberculin test was able to transfer to a healthy receptor the ability to respond 
to this test (Lawrence, 1955). DLE are constituted by a group of numerous molecules all of 
them with a molecular weight between 1-6 KDa. DLE have been widely used as adjuvant for 
treating patients with infectious diseases, and deficient cell-mediated immune response 
(Wilson et al., 1984; Berrón et al., 2007). Transfer factors bind to antigens in an 
immunologically specific manner. This reactivity probably explains the specificity of 
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individual transfer factors; it appears the purified materials are immunologically active and 
antigen-specific. (Kirckpatrick, 1993). 
The most consistent effects of transfer factors on the immune system are expression of 
delayed-type hypersensitivity (DTH) and production of cytokines. DLE are able to induce 
secretion of macrophage migration inhibitory factor (Kirckpatrick, 1993), to restore the 
expression of TNF and iNOS in a mouse model of tuberculosis, provoking inhibition of 
bacterial proliferation and significant increase of DTH (Fabre et al., 2004), and to induce 
expression of mRNA and IFN- in peripheral blood mononuclear cells from animal models 
and during treatment of human diseases (Estrada-Parra et al., 1998; Pineda et al., 2005; 
Luna-Baca et al., 2007; Santacruz-Valdes et al., 2010). Immune modulation induced by DLE 
therapy increase IFN-+ cells promoting Th1 response and restoring a Th2 balance, thus 
treatment with DLE has also been used in allergic diseases, such as AD (Sosa et al., 2001; 
Flores-Sandoval et al., 2005) and asthma (Valdés-Sánchez et al., 1993), in both diseases with 
promissory results, particularly in moderate persistent allergic asthma, helping to reduce 
the use of inhaled glucocorticoids (Espinosa Padilla et al., 2009). AOD treatment with DLE 
has not been enough studied yet; nonetheless, preliminary reports suggest that DLE 
improves clinical outcome in patients with negative skin reactivity to allergens, suggesting 
that DLE therapy could be used as therapeutic tool in such patients. (Jiménez-Martínez et 
al., 2010). However, more research is required to better understand exact indications of DLE 
in all types of AOD. 
6. Biomarkers research and its applications in allergic ocular diseases 
Biomarkers are common molecules, such as lipids, glycans or proteins, located in tissues, 
cells and secretions. Changes in concentration of these molecules, indicates a biological 
status from “normal” to “pathological” range. Biomarkers can be used as prognostic or 
diagnostic tools or as a target to new therapies (Hoffmann-Sommergruber et al., 2011). In 
this context proteomics, immunomics and bioinformatics could aid to explore and to know 
antigens recognized by immune system during allergic response. 
Immunome is defined as the proteome subset of an antigen, recognized by the immune 
receptors (TCR or BCR) and the tools that help us to study immunome are named 
immunomics (De Groot, 2006). Exists different ways to analyze immunome, searching in 
immunome epitope databases could give us newly identified epitope; however, most 
databases involved TCR epitopes exclusively (Sette et al., 2005). To generate a functional 
profile for allergic conjunctivitis patients we can select epitopes from the growing, verified 
database of B cell epitopes (Prechl et al., 2010) but in the case of allergies is needed to know 
a biomarker candidate, this is only possible if we know the frequency of allergens in our 
population. Once we have an exploratory biomarker (most frequent allergen recognized by 
patients IgE antibodies), it could be used as a potential precursor for probable useful 
biomarker. Protein sequencing, and other functional procedures to evaluate functional 
proteins (i.e. ELISA, flow cytometry, immune histologyc techniques), followed by analytical 
test system (bioinformatics) could lead to identification or prediction of protein structure. 
(Goodsaid & Frueh, 2006). The last step in biomarker research is related to practical 
validation of putative biomarkers. If the new biomarker is related to diagnostic, studies 
should support specificity and sensitivity of the exploratory biomarker (Wilkins et al., 2006). 
Finally cross-validation processes will include independent validation of new biomarker by 
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several researchers, and if results are reproducible, the biomarker may be considered valid 
(Hardouin et al., 2006).  
All this process is needed to know peptides recognized by IgE antibody in allergic disease. 
Knowledge could be used to develop diagnostic test i.e. determination of specific IgE in 
tears or to develop second generation immunotherapy. Recombinant DNA technology could 
be used to obtain highly purified allergens in their native conformation. The recombinant 
allergens could then formulated with ad hoc adjuvants and/or mucoadhesive excipients so 
that they specifically target oral Langerhans cells and induce allergen-specific regulatory T 
cells (Moingeon, 2006). 
 
 
 
 
 
Fig. 3. Research flow in biomarkers related to allergic diseases. 
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7. Conclusions 
Allergic ocular diseases have become a special concern for clinical and basic research. Their 
impact on quality of life among individuals, annually represent an important issue of 
investment to find better treatments, particularly to control the effects of chronic diseases 
which could threat vision and influence on daily life activities. Clinical diagnosis is still a 
challenger due to a wide range of overlapping entities which might respond differently to 
conventional treatments; such heterogeneity is important to be considered not only to focus 
on the ocular problem, but to approach the problem with an interdisciplinary medical 
group, including allergist/immunologist, ENT specialists, and dermatologist; all working 
together to improve ocular and systemic health of the allergic patient. Despite that 
important discoveries about immune pathophysiological mechanisms has brought light into 
the problem, there is not enough. Research efforts need to be also directed to the discovery 
of biomarkers and immune therapeutic management to control both, sensitization and 
effector phases of AOD. Knowledge about the molecular mechanisms involved, together 
with an interdisciplinary treatment group will support better results in allergic 
conjunctivitis patients. 
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